MARK LEES

Vice President – Corporate Strategy and Operations, Mestag Therapeutics

Mark Lees is VP Strategy and Operations at Mestag Therapeutics. He previously worked in strategic and operational roles at F-star Therapeutics, a UK immuno-oncology company with a bispecific antibody platform, and Immunocore, where he supported the leadership team in developing a unique soluble T-cell receptor technology. At a UCL spin-out, Mark managed preclinical gene therapy and oncology programmes towards the clinic. Before the move into biotech, Mark worked in management consulting as well as at England’s National Institute for Health Research. Mark holds a Biochemistry degree from Oxford, a PhD in the genetic basis of autoimmune disease from Imperial College London, and an MBA from Oxford’s Said Business School.